Nutra Pharma Corp (NPHC) Cash & Equivalents (2010 - 2026)

Nutra Pharma has disclosed Cash & Equivalents across 16 years of filings, most recently posting $250000.0 for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 216.18% year-over-year to $250000.0; the TTM figure through Jun 2026 stood at $250000.0 (up 216.18% YoY), while the FY2025 annual figure was $12181.0, down 66.58% from the prior year.
• Cash & Equivalents came in at $250000.0 for Q2 2026 at Nutra Pharma, roughly flat from $250000.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $250000.0 in Q1 2024 to a low of $6939.0 in Q1 2022.
• Average Cash & Equivalents over 4 years is $138243.9, with a median of $164534.5 recorded in 2024.
• Year-over-year, Cash & Equivalents tumbled 94.46% in 2025 and jumped 1705.97% in 2026.
• Over 4 years, Cash & Equivalents stood at $10448.0 in 2022, then jumped by 248.84% to $36447.0 in 2024, then slumped by 66.58% to $12181.0 in 2025, then soared by 1952.38% to $250000.0 in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $250000.0 in Q2 2026, $250000.0 in Q1 2026, and $12181.0 in Q4 2025.